CTi Biopharma Corp (CTIC)

3.010
-0.040(-1.31%)
  • Volume:
    653,957
  • Bid/Ask:
    3.000/3.150
  • Day's Range:
    2.980 - 3.040
  • Type:Equity
  • Market:United States
  • ISIN:US12648L6011
  • CUSIP:00012648L601

CTIC Overview

Prev. Close
3.05
Day's Range
2.98-3.04
Revenue
-
Open
2.98
52 wk Range
1-4.07
EPS
-0.79
Volume
653,957
Market Cap
280.85M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
729,951
P/E Ratio
-
Beta
0.75
1-Year Change
166.37%
Shares Outstanding
93,304,923
Next Earnings Date
Nov 08, 2021
What is your sentiment on CTi Biopharma Corp?
or
Market is currently closed. Voting is open during market hours.

CTi Biopharma Corp News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuySellSellBuyBuy
Technical IndicatorsStrong BuyBuyStrong SellSellStrong Buy
SummaryStrong BuyNeutralStrong SellNeutralStrong Buy

CTi Biopharma Corp Company Profile

CTi Biopharma Corp Company Profile

Employees
22

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Read More
  • Are we going to have a big spike soon or a big pull back?¿
    0
    • take care guys of high price they are going to make offers soonest with 51mlln $ and the price will drop down
      0
      • Scrivi i tuoi pensieri su CTi Biopharma Corp
        0
        • Holding long and strong
          0
      • Hello Folks, is it possible CTIC outperform above?  Current Price US$3.49 Fair Value US$41.87 Found it on SimplyWall
        0
        • RDGL approval or denial by Jan 16 by the FDA for breakthrough designation for their tumor fighting drug
          0
          • RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
            0
            • 30 novembre 2020 07:00 EST 30 novembre 2020 07:00 EST CTI BioPharma annuncia la pubblicazione dell'articolo Evidenziando i dati Pacritinib dallo studio PAC203 Phase 2 in Mielofibrosi nei progressi del sangue CTI BioPharma annuncia la pubblicazione dell'articolo Evidenziando i dati Pacritinib dallo studio PAC203 Fase 2 a Mielofibrosi nei progressi del sangue Scrivi i tuoi pensieri su CTi Biopharma Corp
              0
              • Ciao! Che ne pensi di CTIC andra' su come le attese?
                0
            • Watching
              0
              • is it halted now?
                0
                • I love ctic
                  0
                  • bought in at 2.36 🤝
                    1
                    • Great pick 👍
                      0
                  • I will take profit at next open.
                    0
                    • Cabincrew get ready for landing🛬🛩
                      0
                      • Will it at least reach $2.50 by end of the day?
                        0
                        • buy buy buy itrm halted
                          0
                          • So that is a reason to buy?
                            0
                        • Guyzzzz fasten your seat belts for 🚀 ROCKETDRIVE
                          0
                          • what is the deal with this kind of rocketing? gonna wait next dip, before i buy in.
                            0
                            • Don't get burnt, pls.
                              0
                              • sky rocketing!!!! https://www.biospace.com/article/releases/cti-biopharma-to-submit-a-new-drug-application-nda-for-the-accelerated-approval-of-pacritinib-for-the-treatment-of-myelofibrosis-patients-with-severe-thrombocytopenia/
                                0
                                • $2 in December
                                  0
                                  • does anyone wonder if this stock will go up or down in the upcoming 30 days?
                                    0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.